Ortho Clinical Diagnostics expands COVID-19 test offerings
19 Aug 2021
Ortho Clinical Diagnostics, one of the world’s largest pure-play in vitro diagnostics companies, has announced its qualitative COVID-19 Total N antibody test received U.S. Food and Drug Administration EUA. This new antibody test is the fifth assay to receive EUA within Ortho’s COVID-19 testing solutions. The test detects the individual’s immune response or total antibodies to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent or prior COVID-19 infection.
Ortho’s new qualitative VITROS® Anti-SARS-CoV-2 Total N antibody test is designed to capture the nucleocapsid protein, detect total antibodies to the COVID-19 virus, and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2. The test offers 99.2% specificity and excellent sensitivity.1 Ortho is the first company to have an EUA for both a quantitative IgG antibody assay targeting the spike protein and a total assay targeting the nucleocapsid protein.
About Ortho’s VITROS® COVID-19 Testing Solutions
Ortho’s VITROS® COVID-19 Testing Solutions help labs meet the demands of the pandemic with reliable, high-throughput testing solutions that offer SARS-CoV-2 infection and antibody testing on Ortho's trusted VITROS® Systems.
Up to 150 antibody tests or up to 130 antigen tests can be processed each hour on Ortho’s VITROS Systems, already installed in more than 1,000 labs across all 50 states in the U.S and in over 5,400 labs across the world.
The VITROS® SARS-CoV-2 Antigen Test is a high-throughput, highly accurate test that detects acute infection of SARS-CoV-2. The VITROS® COVID-19 antibody tests include IgG and Total tests that target the S1 spike protein.
The VITROS® COVID-19 Performance Dashboard allows labs to easily view COVID-19 antibody testing data and enables more informed decisions. The web-based system provides productivity information regarding Ortho analyzers, test volumes, workload balance, sample quality metrics, and reagent efficiency.
Do you use Ortho Clinical Diagnostics products in your lab? Write a review today for your chance to win a $400 Amazon gift card>>
Related Products
Request Quote for All Products
VITROS® XT 7600 Integrated System
Ortho Clinical DiagnosticsVITROS® XT Systems embrace digital chemistry and are powered by a new digital reflectometer, connecting your lab's ecosystem better than ever before, driving your efficiency, productivity and improving the quality of care you can provide to your patients.
VITROS® 250/350 Chemistry System
Ortho Clinical DiagnosticsProviding fast, accurate results is a necessity—even for small labs—with growing pressure to reduce errors and cut costs in the midst of increased demands and significant staffing shortages. The VITROS® 350 System is a compact chemistry system designed to be efficient, dependable, and, above all, easy to use as a primary, STAT, or backup system. The VITROS® 250/350 System menu of quality assays includes assays in these disease areas: Chemistry TDM Proteins Diabetes
ORTHO VISION™ Analyzer
Ortho Clinical DiagnosticsIntroducing the ORTHO VISION™ Analyzer—the system with the power to transform transfusion medicine The ORTHO VISION™ Analyzer was developed to meet the unique needs of immunohematology labs through the proprietary benefits of Responsive Automation. This intuitive system brings you improvements with: Secure monitoring technologies Dynamic workflow management Interactive partnership with Ortho Clinical Diagnostics The ORTHO VISION™ Analyzer not only raises the bar in transfusion medicine, it redefines it. Only the ORTHO VISION™ Analyzer utilizes Responsive Automation to bring immunohematology labs the future of transfusion medicine.